{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:29:07Z","timestamp":1790825347399,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejphar.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T08:48:23Z","timestamp":1489222103000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro"],"prefix":"10.1016","volume":"804","author":[{"given":"James A.","family":"Angus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Soeding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.03.014_bib1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1056-8719(00)00121-0","article-title":"Techniques to study the pharmacodynamics of isolated large and small blood vessels","volume":"44","author":"Angus","year":"2000","journal-title":"J. Pharmacol. Toxicol. Meth."},{"key":"10.1016\/j.ejphar.2017.03.014_bib2","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1021\/jm031115r","article-title":"Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists","volume":"47","author":"Bolli","year":"2004","journal-title":"J. Med Chem."},{"key":"10.1016\/j.ejphar.2017.03.014_bib3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1113\/jphysiol.1926.sp002315","article-title":"The antagonism of acetyl choline by atropine","volume":"61","author":"Clark","year":"1926","journal-title":"J. Physiol. (Lond.)"},{"key":"10.1016\/j.ejphar.2017.03.014_bib4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/365759a0","article-title":"Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist","volume":"365","author":"Clozel","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2017.03.014_bib5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/00005344-200201000-00014","article-title":"Endothelin receptors in cultured and native human radial artery smooth muscle","volume":"39","author":"Conant","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.03.014_bib6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/j.1476-5381.1993.tb13938.x","article-title":"Endothelin receptor subtypes in human and guinea-pig pulmonary tissues","volume":"110","author":"Hay","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.03.014_bib7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.03.014_bib8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.1994.134","article-title":"Pharmacologic target-mediated drug disposition","volume":"56","author":"Levy","year":"1994","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.ejphar.2017.03.014_bib9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0165-6147(00)89066-5","article-title":"Analysis of competitive agonist-antagonist interactions by nonlinear regression","volume":"16","author":"Lew","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2017.03.014_bib10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1042\/cs0900091","article-title":"Unique response of human arteries to endothelin B receptor agonist and antagonist","volume":"90","author":"Liu","year":"1996","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2017.03.014_bib11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1476-5381.1995.tb16338.x","article-title":"ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro","volume":"115","author":"Maguire","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.03.014_bib12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.lfs.2012.05.008","article-title":"Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues","volume":"91","author":"Maguire","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2017.03.014_bib13","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1093\/eurheartj\/ehn234","article-title":"Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?","volume":"29","author":"Opitz","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2017.03.014_bib14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1021\/jm960274q","article-title":"Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists","volume":"39","author":"Riechers","year":"1996","journal-title":"J. Med Chem."},{"key":"10.1016\/j.ejphar.2017.03.014_bib15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pupt.2009.01.006","article-title":"Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels","volume":"22","author":"Sauvageau","year":"2009","journal-title":"Pulm. Pharm. Ther."},{"key":"10.1016\/j.ejphar.2017.03.014_bib16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1517\/17425255.2015.1000859","article-title":"Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension","volume":"11","author":"Sidharta","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2017.03.014_bib17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1177\/0091270008324180","article-title":"Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers","volume":"48","author":"Spence","year":"2008","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.ejphar.2017.03.014_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-3565(25)31472-2","article-title":"Developments of computer-based estimation of pA2 values and associated analysis","volume":"207","author":"Stone","year":"1978","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.03.014_bib19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","article-title":"Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects","volume":"60","author":"Weber","year":"1996","journal-title":"Clin. Pharm. Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917301656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917301656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:19:21Z","timestamp":1750097961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917301656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":19,"alternative-id":["S0014299917301656"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.03.014","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}